PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Parent market • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2019 • Market size and forecast 2019-2024 • Market outlook PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY TYPE • Market segmentation by type • Comparison by type • Anxiety - Market size and forecast 2019-2024 • Panic disorders - Market size and forecast 2019-2024 • Others - Market size and forecast 2019-2024 • Market opportunity by type PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2019-2024 • Europe - Market size and forecast 2019-2024 • Asia - Market size and forecast 2019-2024 • ROW - Market size and forecast 2019-2024 • Key leading countries • Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS • Drug reformulations • Use of alprazolam in new research areas • Increasing geriatric population prone to anxiety PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Amneal Pharmaceuticals Inc. • Cadila Healthcare Ltd. • Endo International Plc • Jazz Pharmaceuticals Plc • Mylan NV • Novartis AG • Pfizer Inc. • Sun Pharmaceutical Industries Ltd. • Teva Pharmaceutical Industries Ltd. • UCB SA PART 14: APPENDIX • Research methodology • List of abbreviations • Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Vendors: Key product offerings Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2019 Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions) Exhibit 09: Global market: Year-over-year growth 2020-2024 (%) Exhibit 10: Five forces analysis 2019 Exhibit 11: Five forces analysis 2024 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2019 Exhibit 18: Type - Market share 2019-2024 (%) Exhibit 19: Comparison by type Exhibit 20: Anxiety - Market size and forecast 2019-2024 ($ millions) Exhibit 21: Anxiety - Year-over-year growth 2020-2024 (%) Exhibit 22: Panic disorders - Market size and forecast 2019-2024 ($ millions) Exhibit 23: Panic disorders - Year-over-year growth 2020-2024 (%) Exhibit 24: Others - Market size and forecast 2019-2024 ($ millions) Exhibit 25: Others - Year-over-year growth 2020-2024 (%) Exhibit 26: Market opportunity by type Exhibit 27: Customer landscape Exhibit 28: Market share by geography 2019-2024 (%) Exhibit 29: Geographic comparison Exhibit 30: North America - Market size and forecast 2019-2024 ($ millions) Exhibit 31: North America - Year-over-year growth 2020-2024 (%) Exhibit 32: Top 3 countries in North America Exhibit 33: Europe - Market size and forecast 2019-2024 ($ millions) Exhibit 34: Europe - Year-over-year growth 2020-2024 (%) Exhibit 35: Top 3 countries in Europe Exhibit 36: Asia - Market size and forecast 2019-2024 ($ millions) Exhibit 37: Asia - Year-over-year growth 2020-2024 (%) Exhibit 38: Top 3 countries in Asia Exhibit 39: ROW - Market size and forecast 2019-2024 ($ millions) Exhibit 40: ROW - Year-over-year growth 2020-2024 (%) Exhibit 41: Top 3 countries in ROW Exhibit 42: Key leading countries Exhibit 43: Market opportunity Exhibit 44: Impact of drivers and challenges Exhibit 45: Growth of geriatric population 2009-2018 (%) Exhibit 46: Vendor landscape Exhibit 47: Landscape disruption Exhibit 48: Vendors covered Exhibit 49: Vendor classification Exhibit 50: Market positioning of vendors Exhibit 51: Amneal Pharmaceuticals Inc. - Vendor overview Exhibit 52: Amneal Pharmaceuticals Inc. - Business segments Exhibit 53: Amneal Pharmaceuticals Inc. - Organizational developments Exhibit 54: Amneal Pharmaceuticals Inc. - Segment focus Exhibit 55: Amneal Pharmaceuticals Inc. - Key offerings Exhibit 56: Amneal Pharmaceuticals Inc. - Key customers Exhibit 57: Cadila Healthcare Ltd. - Vendor overview Exhibit 58: Cadila Healthcare Ltd. - Business segments Exhibit 59: Cadila Healthcare Ltd. - Organizational developments Exhibit 60: Cadila Healthcare Ltd. - Geographic focus Exhibit 61: Cadila Healthcare Ltd. - Key offerings Exhibit 62: Cadila Healthcare Ltd. - Key customers Exhibit 63: Endo International Plc - Vendor overview Exhibit 64: Endo International Plc - Business segments Exhibit 65: Endo International Plc - Organizational developments Exhibit 66: Endo International Plc - Geographic focus Exhibit 67: Endo International Plc - Segment focus Exhibit 68: Endo International Plc - Key offerings Exhibit 69: Endo International Plc - Key customers Exhibit 70: Jazz Pharmaceuticals Plc - Vendor overview Exhibit 71: Jazz Pharmaceuticals Plc - Business segments Exhibit 72: Jazz Pharmaceuticals Plc - Organizational developments Exhibit 73: Jazz Pharmaceuticals Plc - Geographic focus Exhibit 74: Jazz Pharmaceuticals Plc - Key offerings Exhibit 75: Jazz Pharmaceuticals Plc - Key customers Exhibit 76: Mylan NV - Vendor overview Exhibit 77: Mylan NV - Product segments Exhibit 78: Mylan NV - Organizational developments Exhibit 79: Mylan NV - Geographic focus Exhibit 80: Mylan NV - Segment focus Exhibit 81: Mylan NV - Key offerings Exhibit 82: Mylan NV - Key customers Exhibit 83: Novartis AG - Vendor overview Exhibit 84: Novartis AG - Business segments Exhibit 85: Novartis AG - Organizational developments Exhibit 86: Novartis AG - Geographic focus Exhibit 87: Novartis AG - Segment focus Exhibit 88: Novartis AG - Key offerings Exhibit 89: Novartis AG - Key customers Exhibit 90: Pfizer Inc. - Vendor overview Exhibit 91: Pfizer Inc. - Business segments Exhibit 92: Pfizer Inc. - Organizational developments Exhibit 93: Pfizer Inc. - Geographic focus Exhibit 94: Pfizer Inc. - Segment focus Exhibit 95: Pfizer Inc. - Key offerings Exhibit 96: Pfizer Inc. - Key customers Exhibit 97: Sun Pharmaceutical Industries Ltd. - Vendor overview Exhibit 98: Sun Pharmaceutical Industries Ltd. - Business segments Exhibit 99: Sun Pharmaceutical Industries Ltd. - Organizational developments Exhibit 100: Sun Pharmaceutical Industries Ltd. - Geographic focus Exhibit 101: Sun Pharmaceutical Industries Ltd. - Key offerings Exhibit 102: Sun Pharmaceutical Industries Ltd. - Key customers Exhibit 103: Teva Pharmaceutical Industries Ltd. - Vendor overview Exhibit 104: Teva Pharmaceutical Industries Ltd. - Business segments Exhibit 105: Teva Pharmaceutical Industries Ltd. - Organizational developments Exhibit 106: Teva Pharmaceutical Industries Ltd. - Segment focus Exhibit 107: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibit 108: Teva Pharmaceutical Industries Ltd. - Key customers Exhibit 109: UCB SA - Vendor overview Exhibit 110: UCB SA - Business segments Exhibit 111: UCB SA - Organizational developments Exhibit 112: UCB SA - Geographic focus Exhibit 113: UCB SA - Key offerings Exhibit 114: UCB SA - Key customers Exhibit 115: Validation techniques employed for market sizing Exhibit 116: Definition of market positioning of vendors

Amneal Pharmaceuticals Inc., Cadila Healthcare Ltd., Endo International Plc, Jazz Pharmaceuticals Plc, Mylan NV, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and UCB SA.